Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"...PluriPain® targeted toward the symptoms of Pre-menstrual syndrome and menstrual pain. Anecdotal and testimonial reports have long noted that users obtain relief from these symptoms with use of the PluriPain® product, and we have made adjustments and additions to the formulation to target these symptoms. Early reports are promising, and we expect marketing efforts to emphasize the usefulness of our product to alleviate PMS-related symptoms. By popular requests, the Company is also working with developers on a menopause supplement.
"We are pursuing scientific surveys and other testing to demonstrate the usefulness of our products. While we do not anticipate developing testing protocols suitable for FDA approvals, we expect anecdotal and testimonial reports that will be useful in our marketing efforts."
" We started to re-launch our internet-based marketing activities in Q1 2023, extending the individual product websites, revamping the Company’s website, continuing to explore wholesale, white-label opportunities and placing products on Amazon."
"To expand its footprint on the Amazon sales channel, we are discussing with Amazon marketing specialist in third party management of our products on Amazon."
" ...exploring marketing prospects in Asia, Australasia, the Middle East, and Europe."
"We are negotiating towards the acquisition of some of these formulations. Currently, other than the two equine formulations where we have the exclusive marketing rights, we do not own the formulations for our key products and manufacture and market them under an agreement with the developer that requires payment of a royalty and a license agreement." Nice future catalyst. Hopefully, soon.
Let the trend be your friend. An oldie but a goodie.
Currently sitting at VWAP. RSI reset. LFG!
BIOADAPTIVES CEO - DR. TED
Dr. Edward E. Jacobs, Jr. (Dr. Ted), a graduate of Princeton University and Harvard Medical school, is a biotechnology consultant with over 25 years experience in biopharmaceutical and medical device development, as well as, 35 years of teaching and direct patient care. Dr. Ted has participated in drug development process from discovery through animal and human studies, including regulatory support for FDA and international regulatory affairs, strategic planning and investor relations.
Dr. Ted has extensive clinical operations experience, having executed more than 15 human trials in the US, Europe, Eastern Europe, and the Republic of South Africa. He has also served as a medical monitor and liaison for clinical investigators involved with international trials with responsibility for regulatory compliance.
In his research, Dr. Ted has made original observations in the field of artificial blood, tissue oxygenation therapy and water modification. His current focus is on natural products for human and animal use, anti-aging strategy, and primitive cell biology. He is an author of more than 40 scientific publications and is the holder of four patents.
Props to Average Joe for spreading the word on Stocktwits. Some may disparage and call it pumping. I call it informing and alerting. Watchlist is growing. Well done.
OTC Stocks to Watch in August 2023
https://www.benzinga.com/pressreleases/23/07/ab33452996/otc-stocks-to-watch-in-august-2023-hnrc-bdpt-enzc-aabb-snnc
T-trade - 6,281,902 @ .00143
Bruce Colclasure, President of BioAdaptives® LiveStock Impact™ division, a well-known and successful livestock nutritionist, breeder, competitor, winner, and owner of numerous champion horses commented “This marks the first of a full line of natural, effective and cost-friendly wellness supplements that will complement each livestock nutrition program. Our Equine Regen Plus® has performed with remarkable success in the past six years. We have now expanded this to provide products that are able to nourish every cell in your livestock’s body with supplements from the earth that are minimally processed, mostly plant-based, and naturally packed with essential nutrients and powerful antioxidants that will help livestock look, feel, and perform at their best. We are excited to continue to offer parallel products to promote wellness and performance in companion pets and other shown animals.”
BIOADAPTIVES PRODUCT ROLL-OUT: LIVESTOCK IMPACT™ EQUINE ALL-IN-ONE™ INTRODUCED AT SHAWNEE SPRING HORSE SALE 6-16-20
U.S. Equestrian Foundation and American Horse Counsel surveys show approximately 7 million horses and over 6 million owners, workers and other service providers in the US involved in recreation, racing, and showing. Equine business has a total annual GDP impact of over $100 billion and over $38 billion spent directly on goods and services relating to equine care. International markets, especially in the Middle East, exceed domestic figures by significant amounts. Our target market is well-defined and exceptionally resistant to economic downturns. True horse people take care of their animals regardless of what is going on elsewhere.
BIOADAPTIVES PRODUCT ROLL-OUT: LIVESTOCK IMPACT™ EQUINE ALL-IN-ONE™ INTRODUCED AT SHAWNEE SPRING HORSE SALE 6-16-20
Thanks! Sent them my appeal for an update using all 4 addresses. I urge all to follow suit. Perhaps the pressure they feel from us collectively can push them to action.
How the money is being used will be revealed, hopefully soon. We know it wasn't for executive compensation. More likely, it's for something positive that will increase share value and interest new investors.
DR. TED - CEO - zero credibility issues
Dr. Edward E. Jacobs, Jr. (Dr. Ted), a graduate of Princeton University and Harvard Medical school, is a biotechnology consultant with over 25 years of experience in biopharmaceutical and medical device development, as well as 35 years of teaching and direct patient care.
Dr. Ted has participated in drug development processes, from discovery through animal and human studies, including regulatory support for FDA, and international regulatory affairs, strategic planning,
and investor relations.
Dr. Ted has extensive clinical operations experience, having executed more than 15 human trials in the U.S., Europe, and South Africa. He has also served as a Medical Monitor and Liaison for clinical investigators involved with international trials, with responsibility for regulatory compliance.
In his research, Dr. Ted has made original observations in the field of artificial blood, tissue oxygenation therapy, and water modification. His current focus is on natural products for human and animal use, anti-aging strategies, and primitive cell biology. He is an author of more than 40 scientific publications, and is the holder of 4 patents.
.0016
Holding and accumulating. Name of the game.
#1 Breakout spot is in our sights. Let's get it for the weekend crowd.
Pretty obvious any substantial PR would launch this rocket.
Let the trend be your friend.
STRONG BUY CANDIDATE
The Bioadaptives Inc stock price gained 35.71% on the last trading day (Thursday, 6th Jul 2023), rising from $0.0014 to $0.0019. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 21 million more shares were traded than the day before. In total, 44 million shares were bought and sold for approximately $82.67 thousand. The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. The Bioadaptives Inc stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Bioadaptives Inc holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months. We have upgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Buy candidate.
https://stockinvest.us/stock/BDPT
#3 on Breakout Board
Up to 25 on the breakout boards. I might just keep posting a while longer. :)
Zero credibility issues for this CEO, a rarity.
DR. TED - CEO
Dr. Edward E. Jacobs, Jr. (Dr. Ted), a graduate of Princeton University and Harvard Medical school, is a biotechnology consultant with over 25 years of experience in biopharmaceutical and medical device development, as well as 35 years of teaching and direct patient care.
Dr. Ted has participated in drug development processes, from discovery through animal and human studies, including regulatory support for FDA, and international regulatory affairs, strategic planning,
and investor relations.
Dr. Ted has extensive clinical operations experience, having executed more than 15 human trials in the U.S., Europe, and South Africa. He has also served as a Medical Monitor and Liaison for clinical investigators involved with international trials, with responsibility for regulatory compliance.
In his research, Dr. Ted has made original observations in the field of artificial blood, tissue oxygenation therapy, and water modification. His current focus is on natural products for human and animal use, anti-aging strategies, and primitive cell biology. He is an author of more than 40 scientific publications, and is the holder of 4 patents.
The Bioadaptives Inc stock price gained 27.27% on the last trading day (Wednesday, 5th Jul 2023), rising from $0.0011 to $0.0014. During the last trading day the stock fluctuated 50.00% from a day low at $0.0010 to a day high of $0.0015. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 14 million more shares were traded than the day before. In total, 22 million shares were bought and sold for approximately $31.45 thousand. The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. The Bioadaptives Inc stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
https://stockinvest.us/stock/BDPT
Over 3 weeks straight as a Buy or Hold candidate on Stockinvest.us
https://stockinvest.us/stock/BDPT
4 of 4 short term indicators = BUY
3 of 4 long term indicators = BUY
2 of 4 med term indicators = BUY
https://www.barchart.com/stocks/quotes/BDPT/opinion
Bought another mil at .012 on the ask this morning. Tag, you're it!
Thanks, PB. Appreciate your invaluable takes! LFG!
BIOADAPTIVES CEO - DR. TED
Dr. Edward E. Jacobs, Jr. (Dr. Ted), a graduate of Princeton University and Harvard Medical school, is a biotechnology consultant with over 25 years experience in biopharmaceutical and medical device development, as well as, 35 years of teaching and direct patient care. Dr. Ted has participated in drug development process from discovery through animal and human studies, including regulatory support for FDA and international regulatory affairs, strategic planning and investor relations.
Dr. Ted has extensive clinical operations experience, having executed more than 15 human trials in the US, Europe, Eastern Europe, and the Republic of South Africa. He has also served as a medical monitor and liaison for clinical investigators involved with international trials with responsibility for regulatory compliance.
In his research, Dr. Ted has made original observations in the field of artificial blood, tissue oxygenation therapy and water modification. His current focus is on natural products for human and animal use, anti-aging strategy, and primitive cell biology. He is an author of more than 40 scientific publications and is the holder of four patents.
Bioswan you are seeing is a Chinese company, Bioswan Laboratories, and yes, their site looks impressive. Bioswan, Inc., however, is (or was) a Nevada corporation, a completely different company.
https://www.sec.gov/Archives/edgar/data/1575142/000126246314000020/bioas1.htm#:~:text=the%20hemp%20market.-,BioSwan%2C%20Inc.,to%20honor%20the%20sublicense%20agreements%20with%20CleanPath%20of%20the%20Ferris%20technology.,-Transfer%20of%20Shares
First post. Been watching, reading, and acquiring shares for a while. LFG!